Testosterone is associated with insulin resistance index independently of adiposity in women with polycystic ovary syndrome

Gynecological Endocrinology

Volumn 34, Issue 1, 2018, Pages 40-44

  Luotola, Kari ^a,b   Piltonen, Terhi T ^c   Puurunen, Johanna ^c   Morin Papunen, Laure C ^c   Tapanainen, Juha S ^a,c  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c OULU UNIVERSITY HOSPITAL   (Finland)

Author keywords

Adiposity; Androgens; Inflammation; Insulin secretion; Insulin sensitivity; Polycystic ovary syndrome

Indexed keywords

ANDROGEN; ATORVASTATIN; C REACTIVE PROTEIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; PLACEBO; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE;

ADULT; ANTHROPOMETRY; ARTICLE; ASSESSMENT OF HUMANS; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; FEMALE; FREE ANDROGEN INDEX; GLUCOSE HOMEOSTASIS; HOMEOSTASIS MODEL ASSESSMENT; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; OBESITY; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; WAIST CIRCUMFERENCE; BLOOD; COMPLICATION; DOUBLE BLIND PROCEDURE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL;

ADIPOSITY; ADULT; ANDROGENS; BODY MASS INDEX; C-REACTIVE PROTEIN; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; FEMALE; GLUCOSE TOLERANCE TEST; HOMEOSTASIS; HUMANS; INFLAMMATION; INSULIN; INSULIN RESISTANCE; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MIDDLE AGED; OBESITY; PLACEBOS; POLYCYSTIC OVARY SYNDROME; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 85021798996     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590.2017.1342793     Document Type: Article

References (29)

1. Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocr Rev 2015;36:487–525.
2. Ollila MM, Piltonen T, Puukka K, et al. Weight gain and dyslipidemia in early adulthood associate with polycystic ovary syndrome: prospective cohort study. J Clin Endocrinol Metab 2016;101:739–47.
3. Hudecova M, Holte J, Olovsson M, et al. Prevalence of the metabolic syndrome in women with a previous diagnosis of polycystic ovary syndrome: long-term follow-up. Fertil Steril 2011;96:1271–4.
4. Schmidt J, Landin-Wilhelmsen K, Brannstrom M, et al. Cardiovascular disease and risk factors in PCOS women of postmenopausal age: a 21- year controlled follow-up study. J Clin Endocrinol Metab 2011;96:3794–803.
5. Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010;95:2038–49.
6. Sokalska A, Piotrowski PC, Rzepczynska IJ, et al. Statins inhibit growth of human theca-interstitial cells in PCOS and non-PCOS tissues independently of cholesterol availability. J Clin Endocrinol Metab 2010;95:5390–4.
7. Ortega I, Cress AB, Wong DH, et al. Simvastatin reduces steroidogenesis by inhibiting Cyp17a1 gene expression in rat ovarian theca-interstitial cells. Biol Reprod 2012;86:1–9.
8. Puurunen J, Piltonen T, Puukka K, et al. Statin therapy worsens insulin sensitivity in women with polycystic ovary syndrome (PCOS): a prospective, randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2013;98:4798–807.
9. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735–42.
10. Perrier S, Darakhshan F, Hajduch E. IL-1 receptor antagonist in metabolic diseases: Dr Jekyll or Mr Hyde? FEBS Lett 2006;580:6289–94.
11. Luotola K, Piltonen TT, Puurunen J, et al. IL-1 receptor antagonist levels are associated with glucose tolerance in polycystic ovary syndrome. Clin Endocrinol (Oxf) 2016;85:430–5.
12. Luotola K, Pietila A, Zeller T, et al. Associations between interleukin-1 (IL-1) gene variations or IL-1 receptor antagonist levels and the development of type 2 diabetes. J Intern Med 2011;269:322–32.
13. Carstensen M, Herder C, Kivimaki M, et al. Accelerated increase in serum interleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010;59:1222–7.
14. Homburg R. Polycystic ovary syndrome – from gynaecological curiosity to multisystem endocrinopathy. Hum Reprod 1996;11:29–39.
15. Matsuda M, DeFronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22:1462–70.
16. Bergman RN. Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach. Diabetes 1989;38: 1512–27.
17. Vrbikova J, Bendlova B, Hill M, et al. Insulin sensitivity and beta-cell function in women with polycystic ovary syndrome. Diabetes Care 2002;25:1217–22.
18. Despres JP, Lemieux I. Abdominal obesity and metabolic syndrome. Nature 2006;444:881–7.
19. Manneras-Holm L, Leonhardt H, Kullberg J, et al. Adipose tissue has aberrant morphology and function in PCOS: enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 2011;96:E304–11.
20. Sathyapalan T, Kilpatrick ES, Coady AM, et al. The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized doubleblind placebo-controlled study. J Clin Endocrinol Metab 2009;94: 103–8.
21. Kaya C, Cengiz SD, Berker B, et al. Comparative effects of atorvastatin and simvastatin on the plasma total homocysteine levels in women with polycystic ovary syndrome: a prospective randomized study. Fertil Steril 2009;92:635–42.
22. Raja-Khan N, Kunselman AR, Hogeman CS, et al. Effects of atorvastatin on vascular function, inflammation, and androgens in women with polycystic ovary syndrome: a double-blind, randomized, placebo-controlled trial. Fertil Steril 2011;95:1849–52.
23. Duleba AJ, Banaszewska B, Spaczynski RZ, et al. Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. Fertil Steril 2006;85: 996–1001.
24. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. J Clin Endocrinol Metab 2009;94: 4938–45.
25. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and metformin on polycystic ovary syndrome after six months of treatment. J Clin Endocrinol Metab 2011;96:3493–501.
26. Banaszewska B, Pawelczyk L, Spaczynski RZ, et al. Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. J Clin Endocrinol Metab 2007;92:456–61.
27. Tosi F, Di Sarra D, Kaufman JM, et al. Total body fat and central fat mass independently predict insulin resistance but not hyperandrogenemia in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2015;100:661–9.
28. O'Reilly MW, Taylor AE, Crabtree NJ, et al. Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione. J Clin Endocrinol Metab 2014;99:1027–36.
29. Xiang AH, Watanabe RM, Buchanan TA. HOMA and Matsuda indices of insulin sensitivity: poor correlation with minimal model-based estimates of insulin sensitivity in longitudinal settings. Diabetologia 2014;57:334–8.